Getting your Trinity Audio player ready...
|
Over a third of patients receiving a new CAR-T cell therapy by Kite Pharma show no signs of cancer after 6 months
Immunotherapy is making rapid progress in treating cancer; offering new options for patients seeking cancer treatment. One of the branches of this field is CAR T cell therapy, which involves editing a patient’s own immune cells to better target and annihilate cancer throughout the body. A promising trial A new CAR T cell therapy developed at the National Cancer Institute and licensed to Kite Pharma in California has shown very encouraging results in a new trial. The study involved patients with non-Hodgkin lymphoma who had run out of other options and would normally only survive around 6 months. Following infusion of the therapy, 36% of patients showed no sign of cancer at a 6 month follow up, and 41% had their cancer shrink to at least half its original size.“The numbers are fantastic. These are heavily treated patients who have no other options. It’s a safe treatment, certainly a lot safer than having progressive lymphoma”
A 62-year-old man with non-Hodgkin lymphoma, at left in December 2015, and three months after treatment with Kite Pharma’s experimental gene therapy. Credit: The American Society for Blood and Marrow Transplantation and Kite. (ASBMT/Kite Pharma via AP)
Copyright © Gowing Life Limited, 2025 • All rights reserved • Registered in England & Wales No. 11774353 • Registered office: Ivy Business Centre, Crown Street, Manchester, M35 9BG.